Pricing Log in Create free account

Biofrontera Inc. (BFRI) vs TherapeuticsMD, Inc. (TXMD)

Biofrontera Inc. and TherapeuticsMD, Inc. are both Drug Manufacturers Specialty & Generic companies. TherapeuticsMD, Inc. is the larger, with a market value of $19.8M against $12.0M — 1.7× the size. TherapeuticsMD, Inc. grew revenue faster over the last twelve months: 27.8% against 17.8%. TherapeuticsMD, Inc. has the higher net margin (−6.64% vs −13.8%) and the higher return on invested capital (−13.8% vs −69.5%). Across the 18 metrics below, TherapeuticsMD, Inc. leads on 13 and Biofrontera Inc. on 5.

Valuation

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 0.23 6.12 2.08
P/B 1.78 0.74 1.79
Price to free cash flow n/m 7.36 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales 0.23 84.46 2.87
Earnings yield (72.84%) (1.35%) (15.94%)
Free cash flow yield (74.83%) 13.59% 0.00%

Profitability

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
Gross margin 79.25% 100.00% 53.51%
Operating margin (14.22%) (120.89%) 0.00%
Net margin (13.78%) (6.64%) (2.45%)
Free cash flow margin (17.17%) 94.71% 0.00%
Return on equity (988.35%) (0.80%) (0.80%)
Return on assets (28.80%) (0.57%) (1.67%)
Return on invested capital (69.45%) (13.77%) 0.00%

Growth

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% 27.78% 5.22%
EPS growth (last fiscal year) 67.70% 73.68% 42.91%
Revenue growth, 5-year CAGR 17.21% (45.84%) 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.00 0.04
Current ratio 1.18 3.22 2.41
Net debt to EBITDA 0.17 2.34 1.01

Dividend

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric BFRI TXMD Drug Manufacturers Specialty & Generic median
Market cap 11.99m 19.80m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack